P&G reaffirms second quarter outlook
This article was originally published in The Rose Sheet
Executive Summary
Fiscal 2002 (ending June 30) sales and earnings expected to be in line with earlier guidance, P&G predicts Dec. 11. Earnings per share likely will exceed last year's levels, but will not reach company's long-term double-digit goal, while sales gains, excluding currency, are expected to be higher than the prior year, but will not reach long-term goal of 4%-6%, P&G says. For the second quarter, both sales and volume are expected to increase at upper end of previous guidance of low single digit growth (1% to 3%), firm adds. Estimates include impact on results from Clairol acquisition. Announcement sparked interest on Wall Street with stock advancing 4.2% to reach 52-week high of 79.9...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.